In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Investors in Recursion Pharmaceuticals Inc (Symbol: RXRX) saw new options begin trading today, for the July 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

) has been revised to $6.12 / share. This is a decrease of 10.64% from the prior estimate of $6.85 dated April 25, 2026. The price target is an average of many targets provided by analysts. The latest ...

Investors in Recursion Pharmaceuticals Inc (Symbol: RXRX) saw new options begin trading this week, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of These 10 Stocks Are Making Big Moves. Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news ...

We recently published 10 Big Names Beating Wall Street at its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Monday. Recursion Pharmaceuticals soared by 13.99 ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...